Thérapies ciblées

25 novembre 2008

Auteurs : A. Méjean, T. Lebret
Référence : Prog Urol, 2008, 18, S228, suppl. S7


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser






Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 ;  246 (4935) : 1306-1309
Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 1989 ;  246 (4935) : 1309-1312
Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction Trends Biochem Sci 2003 ;  28 (9) : 488-494 [cross-ref]
Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective Clin Cancer Res 2006 ;  12 (17) : 5018-5022 [cross-ref]
Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 2008 ;  8 (8) : 579-591 [cross-ref]
Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 2005 ;  438 (7069) : 820-827 [cross-ref]
Yang A.D., Bauer T.W., Camp E.R., Somcio R., Liu W., Fan F., Ellis L.M. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy Cancer 2005 ;  103 (8) : 1561-1570 [cross-ref]
Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 2006 ;  5 (8) : 671-688 [cross-ref]
Sardari Nia P., Hendriks J., Friedel G., Van Schil P., Van Marck E. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma Histopathology 2007 ;  51 (3) : 354-361 [cross-ref]
Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us J Natl Cancer Inst 2002 ;  94 (12) : 883-893 [cross-ref]
Bruns C.J., Liu W., Davis D.W., Shaheen R.M., McConkey D.J., Wilson M.R., Bucana C.D., Hicklin D.J., Ellis L.M. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases Cancer 2000 ;  89 (3) : 488-499 [cross-ref]
Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 2007 ;  8 (11) : 975-984 [inter-ref]
Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 2007 ;  356 (2) : 115-124 [cross-ref]
Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 ;  356 (2) : 125-134 [cross-ref]
Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 ;  370 (9605) : 2103-2111 [cross-ref]
Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 2008 ;  372 (9637) : 449-456 [cross-ref]
Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 2007 ;  356 (22) : 2271-2281 [cross-ref]
Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 2004 ;  10 (2) : 145-147 [cross-ref]
Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 ;  307 (5706) : 58-62 [cross-ref]
Dickson P.V., Hamner J.B., Sims T.L., Fraga C.H., Ng C.Y., Rajasekeran S., Hagedorn N.L., McCarville M.B., Stewart C.F., Davidoff A.M. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clin Cancer Res 2007 ;  13 (13) : 3942-3950 [cross-ref]
Franco M., Man S., Chen L., Emmenegger U., Shaked Y., Cheung A.M., Brown A.S., Hicklin D.J., Foster F.S., Kerbel R.S. Targeted antivascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia Cancer Res 2006 ;  66 (7) : 3639-3648 [cross-ref]
Mimura K., Kono K., Takahashi A., Kawaguchi Y., Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2 Cancer Immunol Immunother 2007 ;  56 (6) : 761-770 [cross-ref]
Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer 2002 ;  2 (7) : 489-501 [cross-ref]
Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 1998 ;  351 (9113) : 1393-1396 [cross-ref]
Hu Q., Klippel A., Muslin A.J., Fantl W.J., Williams L.T. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase Science 1995 ;  268 (5207) : 100-102
Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of RAP/Mtor Proc Natl Acad Sci U S A 2001 ;  98 (18) : 10314-10319 [cross-ref]
Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 2002 ;  8 (2) : 128-135 [cross-ref]


© 2008  Elsevier Masson SAS. Tous droits réservés.